KeyBanc raised its price target on CryoPort (NASDAQ:CYRX) to $17 from $15, maintaining an Overweight rating. The firm cited improved revenue visibility compared to the COVID era and margins expected to expand through 2028.
The stock surged 93% over the past year, trading near its 52-week high of $13.79. KeyBanc analyst Paul Knight noted, 'Revenue visibility is higher and quality is better than the COVID era.'
Knight added that long-term EBITDA margin goals of 30% are conservative versus peers, and the FY28 EV/EBITDA multiple should expand. He concluded by raising the price target to $17.
Bond.az data suggests the stock may appear overvalued relative to fair value. CryoPort recently reported Q1 FY26 revenue of $47.8 million, beating consensus estimates.
